Environmental

REGN's high R&D intensity supports a lower-emissions, science-led operating model versus manufacturing-heavy peers, though laboratory energy use still creates material footprint exposure.

The company appears less exposed to direct Scope 1 and 2 intensity than large-scale industrial peers because its value creation is concentrated in research rather than asset-heavy production.

No major environmental controversies are indicated in the provided data, which supports a cleaner relative profile versus peers with more visible manufacturing or waste-management risks.

Environmental risk remains tied to supply-chain and product-development activities, but these are generally less structurally burdensome than the physical-transition risks faced by heavier peers.

Social

REGN's R&D-heavy model supports high-skilled employment and scientific talent retention, which is typically a stronger social profile than peers with more labor-intensive operations.

The company's low stock-based compensation to revenue suggests comparatively restrained dilution pressure, which can support employee alignment versus peers with heavier equity compensation use.

Biopharma peers face elevated patient-safety and access expectations, and REGN's research focus makes these issues material, but no specific adverse social controversy is evident in the provided data.

Social risk is concentrated in product quality, clinical integrity, and access perceptions, yet the available metrics suggest a relatively disciplined operating profile versus peers.

Governance

REGN's very low debt-to-equity ratio indicates conservative balance-sheet governance versus more leveraged peers, reducing creditor pressure and financial-risk spillover.

Negative net debt to EBITDA suggests net cash positioning, which typically gives management more flexibility and less refinancing risk than peers with higher leverage.

Stock-based compensation at 6.4% of revenue appears moderate for a growth-oriented biotech company, implying better capital discipline than peers with more aggressive equity issuance.

The high R&D spend to revenue reflects a governance model centered on long-duration innovation investment, which is generally credible versus peers if capital allocation remains disciplined.

Overall Score

REGN screens as a strong ESG relative to peers, led by conservative leverage, disciplined compensation, and a research-led operating model that limits several structural ESG risks.

Score Driver: Conservative Balance-Sheet Governance Is The Clearest Relative Advantage Versus Peers.